A 2024 review of BTK inhibitors in chronic lym... - CLL Support
A 2024 review of BTK inhibitors in chronic lymphocytic leukemia
You need to be a member of this community to see this post.
Read more about...
- Clinical trials
- Ibrutinib
- Rituximab
- Venetoclax
- Combination therapy
- Obinutuzumab
- FCR
- Chronic leukaemia
- Acalabrutinib
10 Replies
You need to be a member of this community to see hidden responses.
Not what you're looking for?
You may also like...
YABTKi or Yet Another BTK inhibitor - an A to Z list of Bruton's Tyrosine Kinase Inhibitors and Degraders following ibrutinib's success
I'll admit that YABTKi is not a recognised CLL related acronym, (acronym lists are here...
BTK inhibitors for the treatment of CLL - the current state of play of 'brutinibs'
In just a short time, in many places, BTK inhibitors (BTKi) have largely replaced...
BRUIN Study: phase 1/2 study of Pirtobrutinib (formerly Loxo 305) in relapsed or refractory B-cell malignancies
Patients discontinue BTKi's due to resistance and intolerance. We evaluated the safety and efficacy...
BTK inhibitor challenges by Dr. Nicole Lamanna
Nicole Lamanna, MD, continues her discussion on BTK inhibitor challenges....
Managing the cardiovascular risk of Bruton's Tyrosine Kinase Inhibitors in chronic lymphocytic leukemia
The American Society of Hematology journal Blood Advances published an important...
Related Posts
- Chronic lymphocytic leukemia treatment algorithm 2022
- Can Venetoclax/Obinituzimab reduce the risk of additional somatic mutations? - Not necessarily. The BTK inhibitors are excellent at....
- Efficacy and safety of new‑generation BTKis (primarily acalabrutinib and zanubrutinib) in CLL/SLL: a systematic review and meta‑analysis
- BTK Degrader Shows Potential for Treating Refractory CLL and SLL
- Advances in Targeted Therapy for R/R CLL OncLive videos & transcripts by Nirav Shah MD & Nicole Lamanna MD
